MRNA Stock Recent News

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season.

In the latest trading session, Moderna (MRNA) closed at $34.01, marking a -1.9% move from the previous day.

Moderna Inc.'s MRNA stock has surged approximately 37% in the last month but has dipped around 15% year to date.

The two collaborated on research showing that quantum computing could greatly aid the design of mRNA-based medicines and treatments.

In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.

Moderna's stock has faced heavy pressure from negative headlines, regulatory setbacks, and political uncertainty, but recent FDA approvals have stabilized sentiment. The company now boasts three approved respiratory vaccines, a strong cash position, and a robust pipeline, supporting a potential long-term growth narrative beyond COVID. Key risks remain: political headwinds, commercial execution, clinical trial outcomes, and high cash burn could impact future performance and investor confidence.

It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the general investment community. But if that company has bright long-term prospects, it's a great idea to stop and take a closer look.

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.